logo-loader
RNS
viewAbbvie

Form 8.3 - AbbVie Inc.

--(BUSINESS WIRE)--  NEW YORK

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

2. INTERESTS ANDSHORT POSITIONS

(a) Interests and short positions (following dealing) in the class ofrelevant security dealt in(Note 3)

(b) Interests and short positionsin relevant securitiesof the company, other than the class dealt in (Note 3)

(Note 4)1. DEALINGS

(a) Purchases and sales

(b) Derivatives transactions (other than options transactions)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasingor varying

(ii) Exercising

(d) Other dealings (including transactions in respect of new securities) (Note 4)

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

(Note 9)Is a Supplemental Form 8 attached?NO

 

TIAA-CREF

Source: TIAA-CREF

(Note 1)of person dealingName

//TIAA-CREF Investment Management, LLCTeachers Advisors, LLCNuveen Asset Management, LLC

Company dealt in

AbbVie Inc.

(Note 2)Class of relevant security to which the dealings being disclosed relate

US Common Stock$0.01

Date of dealing

07 May 2020

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

17,998,383 1.219%

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

17,998,383 1.219%

 

 

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

N/A

N/A

 

(2) Derivatives (other than options)

N/A

N/A

 

(3) Options and agreements to purchase/sell

N/A

N/A

Total

N/A

N/A

 

 

Purchase/sale

 

Number of relevant securities

 

(Note 5)Price per unit

Sale

4,000

$85.42

Sale

334

 

$84.19

Sale

5,767

$84.22

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

N/A

N/A

N/A

N/A

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

(Note 7)Number of securities to which the option relates

Exercise price

Type, e.g. American, European etc.

Expiry date

(Note 5)Option money paid/received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Product name,

e.g. call option

Number of securities

(Note 5)Exercise price per unit

N/A

N/A

N/A

Nature of transaction

(Note 8)

Details

Price per unit

(Note 5)(if applicable)

N/A

N/A

N/A

Date of disclosure

08 May 2020

Contact name

Stuart R. Brunet

Telephone number

+1 (415) 882-3711

If a connected EFM, name of offeree/offeror with which connected

N/A

(Note 10)If a connected EFM, state nature of connection

N/A

Quick facts: Abbvie

Price: 96.83

Market: NYSE
Market Cap: $170.65 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE